For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 0 | 17,851* | 2,764 | 11,476 |
| Impairment of long-lived assets | 0 | -1,927* | 3,855 | 0 |
| Research and development | 98,162 | 87,844* | 74,094 | 78,388 |
| General and administrative | 20,357 | 15,716* | 17,336 | 17,645 |
| Total operating expenses | 118,519 | 101,632* | 95,285 | 96,033 |
| Loss from operations | -84,154 | -83,781* | -92,521 | -84,557 |
| Interest and other income | 14,981 | 10,676* | 10,444 | 8,051 |
| Interest and other expense | 61 | 61* | 98 | 108 |
| Total other income | 14,920 | 10,615* | 10,346 | 7,943 |
| Net loss | -69,234 | -73,167* | -82,175 | -76,614 |
| Unrealized gain on marketable securities | -5,994 | 947* | 1,222 | 337 |
| Total comprehensive loss | -75,228 | -72,221 | -80,953 | -76,277 |
| Basic EPS | -0.71 | -0.843 | -0.94 | -0.95 |
| Diluted EPS | -0.71 | -0.843 | -0.94 | -0.95 |
| Basic Average Shares | 97,534,269 | 85,722,064 | 87,300,286 | 80,449,405 |
| Diluted Average Shares | 97,534,269 | 85,722,064 | 87,300,286 | 80,449,405 |
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)